Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05196867 · ClinicalTrials.gov registry record · NA
Liver Cancer Prevention Randomized Control Trial
A NA study of Cirrhosis, Liver and Liver Diseases, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT05196867: Active NA study of Cirrhosis, Liver and Liver Diseases, sponsored by M.D. Anderson Cancer Center.
NCT05196867 is a NA study of Cirrhosis, Liver and Liver Diseases that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 49 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05196867, a NA study of Cirrhosis, Liver and Liver Diseases, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effectiveness of a behaviorally-based tailored disease management intervention in patients with fibrosis or steatosis and risk factors for cirrhosis.
Primary Outcome
a serum-based biomarker of fibrosis
Conditions Studied
Interventions
- BEHAVIORAL Intervention Group
- BEHAVIORAL Control Group
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2028-08-30 |
| Phase | NA |
What the registry record for NCT05196867 still lists
NCT05196867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 2 interventions - of which Intervention Group is the first listed.
NCT05196867 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05196867 about?
NCT05196867 is a clinical study titled "Liver Cancer Prevention Randomized Control Trial". To determine the effectiveness of a behaviorally-based tailored disease management intervention in patients with fibrosis or steatosis and risk factors for cirrhosis.
What is the current status of trial NCT05196867?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 49 participants. The study started on 2022-02-11. Estimated completion is 2028-08-30.
What conditions does trial NCT05196867 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Liver Diseases, Fibrosis, Liver.
What interventions are being tested in trial NCT05196867?
The interventions under investigation include: Intervention Group (BEHAVIORAL), Control Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT05196867?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05196867 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05196867's enrollment target sits among peer trials
49 23rd of 34 higher than 12 of 34 other Cirrhosis, Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis, Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
RECRUITING · NA
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
RECRUITING · NA
-
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
RECRUITING · NA
-
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI